NO20035025D0 - Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer - Google Patents

Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer

Info

Publication number
NO20035025D0
NO20035025D0 NO20035025A NO20035025A NO20035025D0 NO 20035025 D0 NO20035025 D0 NO 20035025D0 NO 20035025 A NO20035025 A NO 20035025A NO 20035025 A NO20035025 A NO 20035025A NO 20035025 D0 NO20035025 D0 NO 20035025D0
Authority
NO
Norway
Prior art keywords
osteopontin
prevention
treatment
neurological disorders
agonist
Prior art date
Application number
NO20035025A
Other languages
English (en)
Other versions
NO20035025L (no
Inventor
Ursula Boschert
Georg Feger
Raghuram Selvaraju
Ruben Papoian
Lilia Bernasconi
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20035025D0 publication Critical patent/NO20035025D0/no
Publication of NO20035025L publication Critical patent/NO20035025L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
NO20035025A 2001-05-17 2003-11-12 Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. NO20035025L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111296 2001-05-17
PCT/EP2002/005081 WO2002092122A2 (en) 2001-05-17 2002-05-08 Use of osteopontin for the treatment and/or prevention of neurologic diseases

Publications (2)

Publication Number Publication Date
NO20035025D0 true NO20035025D0 (no) 2003-11-12
NO20035025L NO20035025L (no) 2003-11-12

Family

ID=8177366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035025A NO20035025L (no) 2001-05-17 2003-11-12 Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.

Country Status (27)

Country Link
US (4) US7217687B2 (no)
EP (1) EP1389130B1 (no)
JP (2) JP4417632B2 (no)
KR (1) KR100947424B1 (no)
CN (2) CN1939538A (no)
AT (1) ATE555803T1 (no)
AU (1) AU2002312886B2 (no)
BG (1) BG108337A (no)
BR (1) BR0209812A (no)
CA (1) CA2443964A1 (no)
CZ (1) CZ20033109A3 (no)
EA (1) EA006655B1 (no)
EE (1) EE200300559A (no)
ES (1) ES2387082T3 (no)
HK (1) HK1067051A1 (no)
HR (1) HRP20030840A2 (no)
HU (1) HUP0400005A3 (no)
IL (2) IL158867A0 (no)
MX (1) MXPA03010327A (no)
NO (1) NO20035025L (no)
NZ (1) NZ528852A (no)
PL (1) PL211763B1 (no)
SK (1) SK14232003A3 (no)
UA (1) UA85368C2 (no)
WO (1) WO2002092122A2 (no)
YU (1) YU89503A (no)
ZA (1) ZA200307956B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446666A1 (en) 2001-05-09 2002-11-14 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
US7282490B2 (en) 2001-11-21 2007-10-16 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CA2489905A1 (en) * 2002-06-25 2003-12-31 Aventis Pharmaceuticals Inc. Osteopontin, oligodendrocytes and myelination
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
CN1791422A (zh) * 2003-03-28 2006-06-21 应用研究系统Ars股份公司 凝聚素在治疗和/或预防周围神经疾病中的用途
JP4509114B2 (ja) * 2003-09-18 2010-07-21 アルラ・フーズ・エイ・エム・ビィ・エイ 幼児用調製乳
JP5456235B2 (ja) * 2003-11-12 2014-03-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経変性疾患を治療するためのワクチン及び方法
US20060264371A1 (en) * 2005-02-18 2006-11-23 Proximagen Ltd. Treatment
US7790687B2 (en) * 2005-02-18 2010-09-07 Proximagen Ltd. Treatment for neurodegeneration
KR20080056302A (ko) 2005-10-13 2008-06-20 안트로제네시스 코포레이션 태반 유래 줄기세포로부터 생산된 희소돌기 아교세포
EP1870107A1 (en) * 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
US20100069254A1 (en) * 2008-09-16 2010-03-18 Laree Hiser Cell Culture Model for Demyelination/Remyelination
KR101449100B1 (ko) * 2011-04-21 2014-10-13 가톨릭대학교 산학협력단 신경세포 데브리스 제거용 오스테오폰틴
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
KR101728808B1 (ko) * 2012-09-28 2017-04-20 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
AU2015308899B2 (en) * 2014-08-27 2020-05-28 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
EP3458036B1 (en) * 2016-05-20 2023-08-23 Cedars-Sinai Medical Center Treating or preventing alzheimer's disease and associated conditions
CN109996810B (zh) * 2016-11-27 2023-08-22 特里同阿盖亚创新公司 从微藻中纯化重组骨桥蛋白的方法
AU2018262805B2 (en) 2017-05-04 2022-02-17 Follicum Ab Peptides for treatment of diabetes
WO2019036331A1 (en) * 2017-08-15 2019-02-21 The Children's Medical Center Corporation OSTEOPONTIN AS A TREATMENT OF NEURONAL INJURIES
TR201903865A2 (tr) * 2019-03-14 2020-09-21 Bogazici Ueniversitesi Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi
WO2021024265A1 (en) * 2019-08-08 2021-02-11 Ramot At Tel-Aviv University Ltd. Methods of treating non-infectious inflammatory disorders
CN111388654A (zh) * 2020-05-22 2020-07-10 南通大学 治疗脊髓损伤的药物、药物试剂盒及方法
WO2021246744A1 (ko) * 2020-06-02 2021-12-09 가톨릭대학교 산학협력단 오스테오폰틴 억제제를 유효성분으로 포함하는 퇴행성 신경계질환의 예방, 개선 또는 치료용 조성물
CN117720620A (zh) * 2023-12-13 2024-03-19 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
MXPA01010332A (es) * 1999-04-15 2002-09-18 Childrens Medical Center Metodos y composiciones para modular una respuesta inmunitaria.
AU3667100A (en) 1999-04-23 2000-11-10 Sulzer Orthopedics Ltd Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
AU782298B2 (en) 1999-10-04 2005-07-14 Nektar Therapeutics Polymer stabilized neuropeptides

Also Published As

Publication number Publication date
CN1533283A (zh) 2004-09-29
AU2002312886B2 (en) 2007-10-25
HRP20030840A2 (en) 2005-08-31
PL211763B1 (pl) 2012-06-29
JP2009191082A (ja) 2009-08-27
US20080213234A1 (en) 2008-09-04
EE200300559A (et) 2004-02-16
KR100947424B1 (ko) 2010-03-12
JP2004536058A (ja) 2004-12-02
EA006655B1 (ru) 2006-02-24
BG108337A (bg) 2004-12-30
CN1939538A (zh) 2007-04-04
US20050176639A1 (en) 2005-08-11
JP4417632B2 (ja) 2010-02-17
HUP0400005A2 (hu) 2004-04-28
IL158867A0 (en) 2004-05-12
NZ528852A (en) 2005-12-23
MXPA03010327A (es) 2004-02-17
JP5036761B2 (ja) 2012-09-26
BR0209812A (pt) 2004-06-01
WO2002092122A2 (en) 2002-11-21
HK1067051A1 (en) 2005-04-01
US20070225214A1 (en) 2007-09-27
ES2387082T3 (es) 2012-09-13
HUP0400005A3 (en) 2012-09-28
US7217687B2 (en) 2007-05-15
ZA200307956B (en) 2004-10-13
EA200301253A1 (ru) 2004-06-24
CA2443964A1 (en) 2002-11-21
ATE555803T1 (de) 2012-05-15
US20040235720A1 (en) 2004-11-25
IL158867A (en) 2010-05-17
CN1286524C (zh) 2006-11-29
PL367065A1 (en) 2005-02-21
NO20035025L (no) 2003-11-12
EP1389130B1 (en) 2012-05-02
EP1389130A2 (en) 2004-02-18
SK14232003A3 (sk) 2004-05-04
CZ20033109A3 (en) 2004-06-16
US7297099B2 (en) 2007-11-20
UA85368C2 (ru) 2009-01-26
KR20040008176A (ko) 2004-01-28
WO2002092122A3 (en) 2003-03-06
YU89503A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
NO20034056D0 (no) Proliferative sykdommer
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
EP1499309A4 (en) PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
WO2001098279A3 (en) Bis-arylsulfones
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
HK1048069A1 (en) Treatment of neurotic disorders.
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
WO2002060373A3 (en) Indole derivatives and their uses as heparanase inhibitors
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.
UA85187C2 (en) 2-aminobenzoyl derivatives
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
WO2004080450A3 (en) Combined use of a fibrate and orlistat for the treatment of obesity
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
AU2003287513A1 (en) INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application